Article info

Download PDFPDF

Extended report
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Free

Authors

  1. Correspondence to Dr Mark Genovese, Stanford University Medical Center, Division of Immunology and Rheumatology, 1000 Welch Road #203, Palo Alto 94304, CA, USA; Genovese{at}Stanford.edu
View Full Text

Citation

Genovese MC, Lee E, Satterwhite J, et al
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

Publication history

  • Accepted March 17, 2013
  • First published April 18, 2013.
Online issue publication 
August 06, 2013

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.